logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5758.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Export All Citations
Copyright © Médecins Sans Frontières
v2.1.5758.produseast1
Showing 1 - 14 of 14 Items
Showing 1 - 14 of 14 Items
Citations
  • Download citations in various formats (CSV, BibTeX, EndNote) for use in reference managers and bibliographies.
  • Current Page (14)
  • CSV
  • BibTeX
  • EndNote
  • All Results (14)
  • CSV
  • BibTeX
  • EndNote
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Bedaquiline resistance and treatment outcomes among patients with tuberculosis previously exposed to bedaquiline in India: A multicentric retrospective cohort study

Singla R, Khan S, Silsarma A, Chavan V, Mahajan R,  et al.
2025-03-13 • Clinical Infectious Diseases
2025-03-13 • Clinical Infectious Diseases

BACKGROUND

Bedaquiline (BDQ) resistance presents a critical challenge in the fight against tuberculosis (TB), particularly multidrug-resistant (MDR) strains. Th...

Journal Article
|
Letter
Conference Material
|
Poster
Journal Article
|
Research
Journal Article
|
Letter
Conference Material
|
Slide Presentation
Conference Material
|
Abstract
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Conference Material
|
Poster
Journal Article
|
Research

Sustained treatment success at 12 months for drug-resistant TB patients on concomitant bedaquiline-delamanid

Chavan V, Silsarma A, Mahajan R, Khan S, Singh P,  et al.
2025-02-01 • IJTLD OPEN
2025-02-01 • IJTLD OPEN

12-month post-treatment outcomes of previously treated drug-resistant tuberculosis patients subsequently treated with concomitant bedaquiline and delamanid +/-carbapenem, in Mumbai, India

Chavan V, Silsarma A, Khan S, Singh P, Iyer A,  et al.
2024-11-08 • MSF Scientific Days Asia 2024
2024-11-08 • MSF Scientific Days Asia 2024

Concomitant bedaquiline and delamanid therapy in patients with drug-resistant extra-pulmonary tuberculosis in Mumbai, India

Mongia H, Mamnoon F, Silsarma A, Mahajan R, Dalal A,  et al.
2024-04-01 • Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
2024-04-01 • Journal of Clinical Tuberculosis and Other Mycobacterial Diseases

BACKGROUND 

World Health Organization suggests concurrent bedaquiline-delamanid (BDQ-DLM) as part of individualised r...

Linezolid resistance in patients with drug-resistant TB

Vengurlekar D, Walker C, Mahajan R, Dalal A, Chavan VV,  et al.
2023-07-01 • International Journal of Tuberculosis and Lung Disease
2023-07-01 • International Journal of Tuberculosis and Lung Disease

High prevalence of bedaquiline and linezolid resistance in extensively drug-resistant tuberculosis patients in a Médecins Sans Frontières clinic, Mumbai, India

Silsarma A, Iyer AS, Galindo MA, Chavan VV, Khan Su,  et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023

High prevalence of bedaquiline and linezolid resistance in extensively drug-resistant tuberculosis patients in a Médecins Sans Frontières clinic, Mumbai, India

Silsarma A, Iyer AS, Galindo MA, Chavan VV, Khan Su,  et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023
INTRODUCTION
Bedaquiline (BDQ) and linezolid (LZD) are Group A drugs and form part of shorter and longer BDQ-based regimens under India’s National Tuberculosis (TB) Programme. A syst...

Surgical interventions for pulmonary tuberculosis in Mumbai, India: Surgical outcomes and programmatic challenges India: surgical outcomes and programmatic challenges

Shirodkar S, Anande L, Dalal A, Desai C, Correa G,  et al.
2016-09-21 • Public Health Action
2016-09-21 • Public Health Action
SETTING
While surgery for pulmonary tuberculosis (PTB) is considered an important adjunct for specific cases, including drug-resistant tuberculosis, operational evidence on its feasi...

Ambulatory management of pre- and extensively drug resistant tuberculosis patients with imipenem delivered through port-a-cath: A mixed methods study on treatment outcomes and challenges

Chavan VV, Dalal A, Nagaraja SB, Thekkur P, Mansoor H,  et al.
2020-06-16 • PLOS One
2020-06-16 • PLOS One
Background
Imipenem, an intravenous antibiotic is recommended for use in drug resistant tuberculosis (DR-TB) when an effective regimen with combination of other second line drugs is...

Resistance Patterns among Multidrug-Resistant Tuberculosis Patients in Greater Metropolitan Mumbai: Trends over Time

Dalal A, Pawaskar A, Das M, Desari R, Prabhudesai P,  et al.
2015-01-21 • PLOS One
2015-01-21 • PLOS One
While the high burden of multidrug-resistant tuberculosis (MDR-TB) itself is a matter of great concern, the emergence and rise of advanced forms of drug-resistance such as extensively dr...

Beyond 'cure' and 'treatment success': quality of life of patients with multidrug-resistant tuberculosis

Laxmeshwar C, Stewart AG, Dalal A, Kumar AMV, Kalaiselvi S,  et al.
2019-01-01 • International Journal of Tuberculosis and Lung Disease
2019-01-01 • International Journal of Tuberculosis and Lung Disease
SETTING
Two drug-resistant tuberculosis (DR-TB) sites (MSF Clinic, Jupiter Hospital) in Mumbai, India.

OBJECTIVE
To assess health-related quality of life (HRQoL) and ass...

One step forward: successful end-of-treatment outcomes of patients with drug-resistant tuberculosis who received concomitant bedaquiline and delamanid in Mumbai, India

Das M, Dalal A, Laxmeshwar C, Ravi S, Mamnoon F,  et al.
2021-11-02 • Clinical Infectious Diseases
2021-11-02 • Clinical Infectious Diseases
BACKGROUND
The Médecins Sans Frontières clinic in Mumbai, India, has been providing concomitant bedaquiline (BDQ) and delamanid (DLM) in treatment regimen for patients with drug-resi...

Treatment outcomes of bedaquiline-exposed tuberculosis patients treated with a regimen containing bedaquiline and delamanid: findings from MSF clinic, Mumbai, India

Mongia H, Mansoor H, Mamnoon F, Silsarma A, Davuluri P,  et al.
2022-05-09 • MSF Scientific Days International 2022
2022-05-09 • MSF Scientific Days International 2022
No abstract available.

One step forward: Successful end-of-treatment outcomes of drug-resistant TB patients who received concomitant bedaquiline and delamanid in Mumbai, India

Das M, Dalal A, Laxmeshwar C, Ravi S, Mamnoon F,  et al.
2020-10-20 • Clinical Infectious Diseases
2020-10-20 • Clinical Infectious Diseases
Background
Médecins Sans Frontières clinic in Mumbai, India has been providing concomitant Bedaquiline (BDQ) and Delamanid (DLM) in treatment regimen for patients with drug-resistan...